EuroInf 2: Subthalamic stimulation, apomorphine, and levodopa infusion in Parkinson's disease

Dafsari, Haidar S.; Martinez‐Martín, Pablo; Rizos, Alexandra; Trošt, Maja; Ghilardi, Maria Gabriela dos Santos; Reddy, Prashanth; Sauerbier, Anna; Petry‐Schmelzer, Jan Niklas; Kramberger, Milica G.; Borgemeester, Robbert W K; Barbe, Michael T.; Ashkan, Keyoumars; Silverdale, Monty; Evans, Julian; Odin, Per; Fonoff, Erich Talamoni; Fink, Gereon R.; Henriksen, Tove; Ebersbach, Georg; Pirtošek, Zvezdan; Visser‐Vandewalle, Veerle; Antonini, Angelo; Timmermann, Lars; Chaudhuri, K. Ray

doi:10.1002/mds.27626

Cited by 134 publications

(141 citation statements)

References 49 publications

Supporting

Mentioning

125

Contrasting

Unclassified

Order By: Relevance

“…Assessment of NMSs in PD are now key to value‐based health care and recommended by patient‐led organizations and the International Parkinson and Movement Disorder Society (IPMDS) . The availability of the NMSS has also allowed NMSs to be assessed in many clinical trials . The impact of NMS burden on quality of life across all stages of PD is now well established, and the NMSS has been used in PD subtyping studies …”

mentioning

confidence: 99%

See 1 more Smart Citation

The Movement Disorder Society Nonmotor Rating Scale: Initial Validation Study

et al. 2019

Self Cite

View full text Add to dashboard Cite

Background The Movement Disorder Society–sponsored Nonmotor Rating Scale is an update of the existing Parkinson's disease Nonmotor Symptoms Scale modified to address some limitations in Nonmotor Symptoms Scale scoring, structure, and symptom coverage. Methods PD patients were recruited from movement disorder centers in an international, multicenter study. The Movement Disorder Society Nonmotor Rating Scale, consisting of 13 domains plus a subscale for nonmotor fluctuations, was rater administered, along with the Nonmotor Symptoms Scale and other clinical assessments. Standard reliability and validity testing were conducted. Results Four hundred and two PD patients were recruited (mean age ± standard deviation, 67.42 ± 9.96 years; mean age at PD onset ± standard deviation, 59.27 ± 10.67 years; median Hoehn and Yahr stage 2 (interquartile range 2–3). Data quality was satisfactory for all Movement Disorder Society Nonmotor Rating Scale domains except sexual (6.7% missing data). There were no floor or ceiling effects for the Movement Disorder Society Nonmotor Rating Scale and nonmotor fluctuations total score; domains had no ceiling effects, but some floor effects (13.5%–83.5%). The Movement Disorder Society Nonmotor Rating Scale and nonmotor fluctuations total score internal consistency were acceptable (average Cronbach's alpha, 0.66 and 0.84, respectively); interrater reliability was excellent (intraclass correlation coefficient, >0.95); for test‐retest reliability, the intraclass correlation coefficient was 0.84 for the Movement Disorder Society Nonmotor Rating Scale and 0.70 for Movement Disorder Society nonmotor fluctuations total score, and precision was excellent for the Movement Disorder Society Nonmotor Rating Scale (standard error of measurement, 25.30) and fair for nonmotor fluctuations (standard error of measurement, 7.06). Correlations between Movement Disorder Society Nonmotor Rating Scale score and the corresponding Nonmotor Symptoms Scale and Movement Disorder Society UPDRS scores were high. There were no significant sex or age effects. The Movement Disorder Society Nonmotor Rating Scale score increased with increasing PD duration, disease severity, and PD medication dose (all P < 0.001). Conclusions The Movement Disorder Society Nonmotor Rating Scale is a valid measure for measuring the burden of a wide range of Nonmotor Rating Scale scores, including nonmotor fluctuations, in PD patients. © 2019 International Parkinson and Movement Disorder Society

show abstract

mentioning

confidence: 99%

“…3 The availability of the NMSS has also allowed NMSs to be assessed in many clinical trials. [4][5][6][7][8][9][10][11][12] The impact of NMS burden on quality of life across all stages of PD is now well established, and the NMSS has been used in PD subtyping studies. 13,14 The NMSS was developed approximately 15 years ago.…”

mentioning

confidence: 99%

The Movement Disorder Society Nonmotor Rating Scale: Initial Validation Study

et al. 2019

Self Cite

View full text Add to dashboard Cite

show abstract

“…In advanced PD continuous intrajejunal infusion of levodopa–carbidopa intestinal gel improves PDQ‐39 up to −10 points . For subcutaneous apomorphine infusion, the PDQ changes range between −0.06 and − 13.2 . In contrast to STN‐DBS, the effect of medication was tested in a short follow‐up of between 8 weeks to 6 months, and the longevity of a positive effect on QoL is lacking.…”

Section: Resultsmentioning

confidence: 99%

The Evolution of Quality of Life After Subthalamic Stimulation for Parkinson's Disease: A Meta‐Analysis

Büttner

Maack

Janitzky

et al. 2019

Movement Disord Clin Pract

View full text Add to dashboard Cite

Background Several studies examined the influence of subthalamic nucleus–deep brain stimulation (STN‐DBS) on quality of life (QoL) in patients with Parkinson's disease (PD). However, it is unclear whether this effect differs between age groups and disease durations and whether it stays consistent over time. Objectives We assessed the influence of stimulation duration, disease duration, and age at surgery on QoL after STN‐DBS. Methods We systematically searched for studies reporting the results of the Parkinson's Disease Questionnaire 39 or 8. Studies were included if they investigated the time passed since STN‐DBS or if their study cohort fell into the range of one of the following age groups: younger than 60 years or between 60 and 70 years. For each condition, a standardized mean difference meta‐analysis was performed. Furthermore, all studies were categorized into short or long disease duration at surgery using a median split. Results A total of 23 studies reporting the cumulative outcome of 76 to 802 PD patients were included in this analysis. The results demonstrate a substantial improvement of QoL after DBS that remains stable over 36 months. QoL falls to preoperative scores 60 months after surgery. However, only 3 studies could be included in this analysis. Both younger and older PD patients profit in QoL from STN‐DBS, independent of the disease duration. Conclusions The results of this analysis show an impressive improvement in QoL after STN‐DBS, with a loss of QoL 60 months after DBS surgery. This highlights the need to explore the factors influencing QoL after STN‐DBS to prevent or delay a decline in QoL.

show abstract

“…This is an ongoing, prospective, observational, multicenter, international study including consecutively enrolled patients from three DBS centers (Cologne, Manchester, and London) as part of the NILS study [9]. It was authorized by local ethics committees (United Kingdom: NRES SouthEast London REC3, 0000010084; 10/H0808/141; Cologne 012-145, German Clinical Trials Register: #6735) and was carried out in accordance with the Declaration of Helsinki.…”

Section: Design and Ethical Approvalmentioning

confidence: 99%

Beneficial effect of 24-month bilateral subthalamic stimulation on quality of sleep in Parkinson’s disease

et al. 2020

Self Cite

View full text Add to dashboard Cite

Background Subthalamic nucleus (STN) deep brain stimulation (DBS) improves quality of life (QoL), motor, and sleep symptoms in Parkinson's disease (PD). However, the long-term effects of STN-DBS on sleep and its relationship with QoL outcome are unclear. Methods In this prospective, observational, multicenter study including 73 PD patients undergoing bilateral STN-DBS, we examined PDSleep Scale (PDSS), PDQuestionnaire-8 (PDQ-8), Scales for Outcomes in PD-motor examination, -activities of daily living, and -complications (SCOPA-A, -B, -C), and levodopa-equivalent daily dose (LEDD) preoperatively, at 5 and 24 months follow-up. Longitudinal changes were analyzed with Friedman-tests or repeated-measures ANOVA, when parametric tests were applicable, and Bonferroni-correction for multiple comparisons. Post-hoc, visits were compared with Wilcoxon signed-rank/t-tests. The magnitude of clinical responses was investigated using effect size.

show abstract

EuroInf 2: Subthalamic stimulation, apomorphine, and levodopa infusion in Parkinson's disease

Cited by 134 publications

References 49 publications

The Movement Disorder Society Nonmotor Rating Scale: Initial Validation Study

The Movement Disorder Society Nonmotor Rating Scale: Initial Validation Study

The Evolution of Quality of Life After Subthalamic Stimulation for Parkinson's Disease: A Meta‐Analysis

Beneficial effect of 24-month bilateral subthalamic stimulation on quality of sleep in Parkinson’s disease

Contact Info

Product

Resources

About